REPORT ID 6547

EMEA (Europe, Middle East and Africa) Dermatomyositis Drug Market Report 2019

Publish Date
2019
Pages
111
Format
Electronic (PDF)

In this report, the EMEA Dermatomyositis Drug market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Dermatomyositis Drug for these regions, from   2019 to 2025 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Dermatomyositis Drug market competition by top manufacturers/players, with Dermatomyositis Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    MedImmune LLC
    Neovacs SA
    Novartis AG
    Octapharma AG
    Pfizer Inc
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Hope Pharmaceuticals Inc
    Idera Pharmaceuticals Inc
    KPI Therapeutics Inc
    Marathon Pharmaceuticals LLC

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Abatacept
    Baricitinib
    Dalazatide
    Immune Globulin
    IMO-8400
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Dermatomyositis Drug Market  Report 2019
1 Dermatomyositis Drug Overview
    1.1 Product Overview and Scope of Dermatomyositis Drug
    1.2 Classification of Dermatomyositis Drug
        1.2.1 EMEA Dermatomyositis Drug Market Size (Sales) Comparison by Type ( 2014-2024)
        1.2.2 EMEA Dermatomyositis Drug Market Size (Sales) Market Share by Type (Product Category)  in 2018
        1.2.3 Abatacept
        1.2.4 Baricitinib
        1.2.5 Dalazatide
        1.2.6 Immune Globulin
        1.2.7 IMO-8400
        1.2.8 Others
    1.3 EMEA Dermatomyositis Drug Market by Application/End Users
        1.3.1 EMEA Dermatomyositis Drug Sales (Volume) and Market Share Comparison by Application ( 2014-2024
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 EMEA Dermatomyositis Drug Market by Region
        1.4.1 EMEA Dermatomyositis Drug Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 Europe Status and Prospect ( 2014-2024)
        1.4.3 Middle East Status and Prospect ( 2014-2024)
        1.4.4 Africa Status and Prospect ( 2014-2024)
    1.5 EMEA Market Size (Value and Volume) of Dermatomyositis Drug ( 2014-2024)
        1.5.1 EMEA Dermatomyositis Drug Sales and Growth Rate ( 2014-2024)
        1.5.2 EMEA Dermatomyositis Drug Revenue and Growth Rate ( 2014-2024)

2 EMEA Dermatomyositis Drug Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Dermatomyositis Drug Market Competition by Players/Manufacturers
        2.1.1 EMEA Dermatomyositis Drug Sales Volume and Market Share of Major Players ( 2014-2019)
        2.1.2 EMEA Dermatomyositis Drug Revenue and Share by Players ( 2014-2019)
        2.1.3 EMEA Dermatomyositis Drug Sale Price by Players ( 2014-2019)
    2.2 EMEA Dermatomyositis Drug (Volume and Value) by Type/Product Category
        2.2.1 EMEA Dermatomyositis Drug Sales and Market Share by Type ( 2014-2019)
        2.2.2 EMEA Dermatomyositis Drug Revenue and Market Share by Type ( 2014-2019)
        2.2.3 EMEA Dermatomyositis Drug Sale Price by Type ( 2014-2019)
    2.3 EMEA Dermatomyositis Drug (Volume) by Application
    2.4 EMEA Dermatomyositis Drug (Volume and Value) by Region
        2.4.1 EMEA Dermatomyositis Drug Sales and Market Share by Region ( 2014-2019)
        2.4.2 EMEA Dermatomyositis Drug Revenue and Market Share by Region ( 2014-2019)
        2.4.3 EMEA Dermatomyositis Drug Sales Price by Region ( 2014-2019)

3 Europe Dermatomyositis Drug (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Dermatomyositis Drug Sales and Value ( 2014-2019)
        3.1.1 Europe Dermatomyositis Drug Sales Volume and Growth Rate ( 2014-2019)
        3.1.2 Europe Dermatomyositis Drug Revenue and Growth Rate ( 2014-2019)
    3.2 Europe Dermatomyositis Drug Sales and Market Share by Type
    3.3 Europe Dermatomyositis Drug Sales and Market Share by Application
    3.4 Europe Dermatomyositis Drug Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Dermatomyositis Drug Sales Volume by Countries ( 2014-2019)
        3.4.2 Europe Dermatomyositis Drug Revenue by Countries ( 2014-2019)
        3.4.3 Germany Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        3.4.4 France Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        3.4.5 UK Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        3.4.6 Russia Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        3.4.7 Italy Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        3.4.8 Benelux Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)

4 Middle East Dermatomyositis Drug (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Dermatomyositis Drug Sales and Value ( 2014-2019)
        4.1.1 Middle East Dermatomyositis Drug Sales Volume and Growth Rate ( 2014-2019)
        4.1.2 Middle East Dermatomyositis Drug Revenue and Growth Rate ( 2014-2019)
    4.2 Middle East Dermatomyositis Drug Sales and Market Share by Type
    4.3 Middle East Dermatomyositis Drug Sales and Market Share by Application
    4.4 Middle East Dermatomyositis Drug Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Dermatomyositis Drug Sales Volume by Countries ( 2014-2019)
        4.4.2 Middle East Dermatomyositis Drug Revenue by Countries ( 2014-2019)
        4.4.3 Saudi Arabia Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        4.4.4 Israel Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        4.4.5 UAE Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        4.4.6 Iran Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)

5 Africa Dermatomyositis Drug (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Dermatomyositis Drug Sales and Value ( 2014-2019)
        5.1.1 Africa Dermatomyositis Drug Sales Volume and Growth Rate ( 2014-2019)
        5.1.2 Africa Dermatomyositis Drug Revenue and Growth Rate ( 2014-2019)
    5.2 Africa Dermatomyositis Drug Sales and Market Share by Type
    5.3 Africa Dermatomyositis Drug Sales and Market Share by Application
    5.4 Africa Dermatomyositis Drug Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Dermatomyositis Drug Sales Volume by Countries ( 2014-2019)
        5.4.2 Africa Dermatomyositis Drug Revenue by Countries ( 2014-2019)
        5.4.3 South Africa Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        5.4.4 Nigeria Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        5.4.5 Egypt Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)
        5.4.6 Algeria Dermatomyositis Drug Sales and Growth Rate ( 2014-2019)

6 EMEA Dermatomyositis Drug Manufacturers/Players Profiles and Sales Data
    6.1 MedImmune LLC
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Dermatomyositis Drug Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Neovacs SA
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Dermatomyositis Drug Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Neovacs SA Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Novartis AG
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Dermatomyositis Drug Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Octapharma AG
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Dermatomyositis Drug Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Pfizer Inc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Dermatomyositis Drug Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 Eli Lilly and Company
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Dermatomyositis Drug Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 F. Hoffmann-La Roche Ltd
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Dermatomyositis Drug Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Hope Pharmaceuticals Inc
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Dermatomyositis Drug Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 Idera Pharmaceuticals Inc
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Dermatomyositis Drug Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 KPI Therapeutics Inc
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Dermatomyositis Drug Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview
    6.11 Marathon Pharmaceuticals LLC

7 Dermatomyositis Drug Manufacturing Cost Analysis
    7.1 Dermatomyositis Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Dermatomyositis Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Dermatomyositis Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Dermatomyositis Drug Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Dermatomyositis Drug Market Forecast ( 2019-2025)
    11.1 EMEA Dermatomyositis Drug Sales, Revenue and Price Forecast ( 2019-2025)
        11.1.1 EMEA Dermatomyositis Drug Sales and Growth Rate Forecast ( 2019-2025)
        11.1.2 EMEA Dermatomyositis Drug Revenue and Growth Rate Forecast ( 2019-2025)
        11.1.3 EMEA Dermatomyositis Drug Price and Trend Forecast ( 2019-2025)
    11.2 EMEA Dermatomyositis Drug Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.3 Europe Dermatomyositis Drug Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.4 Middle Eastt Dermatomyositis Drug Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.5 Africa Dermatomyositis Drug Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.6 EMEA Dermatomyositis Drug Sales Forecast by Type ( 2019-2025)
    11.7 EMEA Dermatomyositis Drug Sales Forecast by Application ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer